等待開盤 09-23 09:30:00 美东时间
+0.260
+3.72%
Journey Medical Corporation (NASDAQ: DERM) announced that its CEO, Claude Maraoui, will attend two investor conferences in September 2026. The first is the Lake Street Capital Markets 10th Annual BIG10 Conference on September 10 in New York City, featuring 1x1 meetings. The second is the H.C. Wainwright 28th Annual Global Investment Conference on September 14, also in NYC, with a presentation and 1x1 meetings. A webcast of the H.C. Wainwright pre...
09-08 20:05
Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...
08-19 20:05
今日重点评级关注:古根海姆:维持Scynexis"买入"评级,目标价从24美元升至33美元;韦德布什:维持Kura Oncology"跑赢大市"评级,目标价从36美元升至38美元
08-14 11:51
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
08-13 21:15
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $17.839 million w...
08-13 04:02
Journey Medical shares are trading higher after the company reported better-tha...
05-15 00:02
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Journey Medical业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收达到1,600万美元,同比增长21%(上年同期为1,310万美元) - AAMROCI净营收为630万美元,较上年同期210万美元大幅增长200% - AAMROCI营收环比增长约26%,主要受益于处方量增长和支付方报销改善 **盈利能力:** - 毛利率为61%,低于上年同期的63.5%,主要因QBREXZA相关的130万美元非现金API库存减值 - 剔除一次性减值后,毛利率约为69%,实现环比和同比改善 - GAAP净亏损2
05-14 12:32
Journey Medical (NASDAQ:DERM) reported first-quarter financial results on Wedne...
05-14 05:17
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same period last year.
05-14 04:04
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11